PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC
George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Craig H. Reynolds, Vijay Gunuganti(Texas Oncology), Jonathan W. Goldman(University of California, Los Angeles), Wen Lin(Shantou University), Kelly L. Bennett(Bristol-Myers Squibb (United States)), David Waterhouse(Oncology Hematology Care), Edward B. Garon(University of California, Los Angeles), Beata Korytowsky(Pfizer (United States)), Donald A. Berry(Berry & Associates (United States)), John A. Glaspy(University of California, Los Angeles), Jin Zhu(Beijing Technology and Business University), Jason C. Chandler(West Cancer Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), David R. Spigel(Sarah Cannon)
Cited by 5
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k